Fibromiyalji ve ayn? zamanda konstipasyon bask?n irritabl barsak sendromu olan olgularda tegaserodun a?r? semptomu üzerine etkisi

摘要

?zet Ama?. Bu ?al??man?n amac? bir 5HT4 agonisti olan tegaserodun fibromyalji sendromlu hastalardaki a?r? üzerine etkisini incelemektir. Y?ntem. Mart-Eylül 2005 aras? hastanemize ba?vuran ve kab?zl?k bask?n irritabl barsak sendromu ile beraberinde fibromyalji tan?s? alan 28 kad?n hasta ?al??maya al?nd?. Hastalar alarm semptomlar? a??s?ndan sorguland? ve organik hastal??? d??lamak i?in gerekli tetkikleri yap?ld?. Hastalara tegaserod 6 mg tablet sabah ak?am yemekten 30 dk ?nce ?eklinde tedavi ba?land?. Hastalar tedavinin 1. ve 2. ay? sonunda kontrole ?a?r?ld?lar. A?r? ?iddetinin belirlenmesi i?in visual analog skala (VAS) kullan?ld?. Bulgular. Hastalar?n tedavinin 1. ve 2. ay? sonundaki VAS de?erleri tedavi ?ncesine g?re dü?ü? g?stermi?tir. De?erler kar??la?t?r?ld???nda aralar?ndaki farkl?l?k ?nemli bulunmu?tur (p<0,05). Sonu?. IBS ve fibromyalji ortak etyopatogeneze sahip hastal?klard?r; ancak tegaserodun piyasadan kald?r?lm?? olmas? bu konuda daha geni? ?apl? ?al??ma yap?lmas?n? k?s?tlamaktad?r. Anahtar kelimeler: ?rritabl barsak sendromu, fibromyalji, tegaserod Abstract Aim. The aim of this study is to investigate the effect of tegaserod which is a the 5HT4 agonist on the symptom of pain in patients with fibromyalgia syndrome. Methods. Twenty-eight female patients who applied to our hospital between March and September 2005 and were diagnosed as constipation-dominant irritable bowel syndrome with fibromyalgia were included in the study. The patients were asked about alarm symptoms and the necessary tests were done to exclude any organic disease. The patients received tegaserod 6 mg tablet 30 min before breakfast and dinner and they were called to their control visits after one and two months of therapy. Visual analog scale (VAS) was used to determine the intensity of pain. Result. The VAS values of the patients after the first and second months decreased significantly (p<0.05) Conclusion: IBS and fibromyalgia are diseases that share the common ethiopathogenesis; but, there is a limitation in planning studies with larger number of patients in this subject as tegaserod has been taken out from the market.